Revisión sistemática. Utilidad clínica del pepsinógeno I/ II en el diagnóstico de la atrofia gástrica y cáncer gástrico

Gastric atrophy increases the risk of gastric cancer due to changes in gastric glands and secretory function. Gastric cancer is a global concern, especially in regions such as South America and East Asia. In Ecuador, it is the leading cause of death, which makes it a major public health problem. The aim of this study is to evaluate the clinical utility of the pepsinogen I/II ratio as a noninvasive biomarker to detect both gastric atrophy and stomach cancer, analyzing its sensitivity, specificity and supportive diagnostic value. For this purpose, a systematic review of the Pubmed, Scielo, Lilacs and Cochrane Library databases was carried out, using the PRISMA method for the selection of publications between 2012 and 2022, excluding gray literature. Thirteen studies were included in this systematic review, evaluated with the JBI tool, which showed moderate to low bias. These studies indicated that the pepsinogen I/II ratio has a sensitivity of 71% and specificity of 83% for detecting gastric atrophy, and a sensitivity of 80% and specificity of 77% for gastric cancer. In addition, twelve studies demonstrated its efficacy as a diagnostic test using the AUC measure, with values of 0.71 for gastric atrophy and 0.80 for cancer. Thus, the pepsinogen I/II ratio shows fair sensitivity and good specificity in the detection of gastric atrophy, and good sensitivity and fair specificity in the case of gastric cancer. The pepsinogen I/II ratio has a regular efficacy for diagnosing gastric atrophy and good for gastric cancer, but its efficiency may be affected by several factors related to diversity and differences between populations and studies performed

• 主要作者: García Vélez, Paola Lissette (author)
• 格式: bachelorThesis
• 語言: spa
• 出版: 2024
• 主題: LABORATORIO CLÍNICO; PEPSINÓGENO; GASTRITIS ATRÓFICA; BIOMARCADOR
• 在線閱讀: https://dspace.unl.edu.ec/jspui/handle/123456789/30468